The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain
During a satellite symposium at the ERA-EDTA in Madrid, Spain, organised by PACE-CME, Luis M Ruilope, MD looked at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.
Video navigation menu
- Diabetes confers an increased risk of CV morbidity and mortality, which is further aggravated by chronic kidney disease 0:09
- Optimal management of diabetes with renal disease implies a broad strategy targeting various risk factors 1:50
- Summary of how CKD complicates management of diabetic patients 6:25
- Unmet needs in management of diabetic patients with CKD 9:04
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
- Luis M Ruilope, MD, Hospital 12 de Octubre Madrid, Spain
This lecture was part of a CME accredited symposium: Managing CKD, Diabetes & CVD: Is epigenetics a new way forward? held at ERA-EDTA in Madrid, Spain.
The symposium was supported by an unrestricted educational grant from Resverlogix Corp